The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
Download from source ↗Dataset overview
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
Abstract
<h4>Background</h4>Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown.<h4>Aims</h4>To establish a faecal microbiota transplantation treatment protocol in ulcerative colitis patients, and to investigate which patient or donor factors are responsible for the treatment success.<h4>Methods</h4>This is an open controlled trial of repeated faecal microbiota transplantation after antibiotic pre-treatment (FMT-group, n = 17) vs antibiotic pre-treatment only (AB-group, n = 10) in 27 therapy refractory ulcerative colitis patients over 90 days. Faecal samples of donors and patients were analysed by 16SrRNA gene-based microbiota analysis.<h4>Results</h4>In the FMT-group, 10/17 (59%) of patients showed a response and 4/17 (24%) a remission to faecal microbiota transplantation. Response to faecal microbiota transplantation was mainly influenced by the taxonomic composition of the donor's microbiota. Stool of donors with a high bacterial richness (observed species remission 946 ± 93 vs no response 797 ± 181 at 15367 rps) and a high relative abundance of Akkermansia muciniphila (3.3 ± 3.1% vs 0.1 ± 0.2%), unclassified Ruminococcaceae (13.8 ± 5.0% vs 7.5 ± 3.7%), and Ruminococcus spp. (4.9 ± 3.5% vs 1.0 ± 0.7%) were more likely to induce remission. In contrast antibiotic treatment alone (AB-group) was poorly tolerated, probably because of a sustained decrease of intestinal microbial richness.<h4>Conclusions</h4>The taxonomic composition of the donor's intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in ulcerative colitis patients. The design of specific microbial preparation might lead to new treatments for ulcerative colitis.
Study facts
- Organism
- —
- Platform
- Illumina MiSeq
- Age group
- —
- Disease groups
- Ulcerative colitis
- Anatomical sites
- —
Data availability
- Analysis code
Strengths & limitations for reuse
Strengths
- Raw reads are advertised
- Analysis code is available
- Participant counts are documented
- Sample counts are documented
Limitations
- Not documented: feature/otu tables are advertised
- Not documented: taxonomic tables are advertised
Extraction evidence & provenance
Each extracted field is shown with the source excerpt and location used to resolve it.
Assay
| Field | Value | Evidence |
|---|---|---|
assay.platform |
Illumina MiSeq from source |
ENA instrument_model=Illumina MiSeq Section |
assay.read_depth_reported |
15376 |
For the analyses, samples were rarefied to at least 15376 sequences/sample. Section |
assay.sequencing_type |
amplicon_16s |
For amplification of bacterial 16S rRNA gene... targeting the hypervariable region V4 Section |
assay.target_region |
V4 |
targeting the hypervariable region V4 of the 16S rRNA gene Section |
Cohort
| Field | Value | Evidence |
|---|---|---|
cohort.disease_activity_metadata_available |
True |
At each study visit, the total Mayo score, faecal calprotectin and a standard laboratory analysis were performed. Section |
cohort.study_design |
longitudinal |
Faecal samples for microbiota analyses were collected at each study visit Section |
cohort.total_participants |
27 |
From June 2012 to July 2014, twenty-seven patients were recruited. Section |
cohort.treatment_exposure_documented |
True |
All patients received antibiotic treatment... Subsequently, 5 faecal microbiota transplantation administrations were performed Section |
cohort.treatment_response_metadata_available |
True |
resulted in a clinical response in 10 out of 17 (59%) patients on day 90 Section |
cohort.ulcerative_colitis_participants |
27 |
in 27 therapy refractory UC patients over 90 days Section |
Data_Assets
| Field | Value | Evidence |
|---|---|---|
data_assets.analysis_code |
True |
More information on statistics and bioinformatic tools applied to the dataset and metadata information can one found at: https://github.com/LGPW/FMT_in_TRUC_APT2017 Section |
data_assets.open_access |
True from source |
"isOpenAccess": "Y" Section |
data_assets.pipeline_or_tool_versions |
True |
Raw files from Illumina MiSeq were processed according to the standard MiSeq SOP of mothur... QIIME version 1.8.0. Section |
data_assets.qc_or_negative_controls_reported |
True |
Sequencing errors were reduced... Chimeras were removed... nonbacterial contaminants... were removed Section |
data_assets.raw_reads |
True |
The generated FASTQ files were used for microbiota analysis. Section |
Specimens
| Field | Value | Evidence |
|---|---|---|
specimens.inflamed_status_available |
True inferred |
Active ulcerative colitis was defined as a total Mayo score ≥4 and an endoscopic subscore ≥1. Section |
specimens.longitudinal_sampling |
True |
Faecal samples for microbiota analyses were collected at each study visit Section |
specimens.number_of_samples |
172 from source |
ENA sample_count=172 Section |
specimens.sample_type |
stool |
Stool samples of patients and donors were immediately frozen and stored at −20°C. Section |